ESMO21: Enhertu brings it’s A game to second-line breast cancerAstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Share XESMO21: Enhertu brings it’s A game to second-line breast cancerhttps://pharmaphorum.com/news/esmo21-enhertu-brings-its-a-game-to-second-line-breast-cancer/
ESMO21: Roche’s giredestrant takes stage in battle of the oral SERDsRoche has revealed the first phase 2 clinical data with giredestrant, one of a clutch of new selective Share XESMO21: Roche’s giredestrant takes stage in battle of the oral SERDshttps://pharmaphorum.com/news/esmo21-roches-giredestrant-takes-stage-in-battle-of-the-oral-serds/
ESMO21: First combo data with Amgen’s Lumakras hit the mark in CRCAmgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting Share XESMO21: First combo data with Amgen’s Lumakras hit the mark in CRChttps://pharmaphorum.com/news/esmo21-first-combo-data-with-amgens-lumakras-hit-the-mark-in-crc/
Immunomedics wows ESMO with breast cancer data revealImmunomedics has revealed the trial data that convinced Gilead to stage a $21 billion takeover, after the biotech’s Share XImmunomedics wows ESMO with breast cancer data revealhttps://pharmaphorum.com/news/immunomedics-wows-esmo-with-breast-cancer-data-reveal/
ESMO 2019 roundupThe European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma Share XESMO 2019 rounduphttps://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/
ESMO 2019 – new data could unlock bigger market for PARP inhibitorsAstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as Share XESMO 2019 – new data could unlock bigger market for PARP inhibitorshttps://pharmaphorum.com/news/esmo-2019-new-data-could-unlock-bigger-market-for-parp-inhibitors/
ESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challengeAmgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported Share XESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challengehttps://pharmaphorum.com/news/esmo-2019-amgens-kras-drug-finds-colorectal-cancer-a-challenge/
As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer dataGlaxoSmithKline and AstraZeneca will go head-to-head with new data on their PARP inhibitor drugs this weekend, as the Share XAs ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer datahttps://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/
Merck KGaA’s bold new approach to cancer immunotherapyGermany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer Share XMerck KGaA’s bold new approach to cancer immunotherapyhttps://pharmaphorum.com/views-analysis-oncology/merck-kgaas-bold-new-approach-to-cancer-immunotherapy/
